A sensitive, reproducible and objective immunofluorescence analysis method of dystrophin in individual fibers in samples from patients with duchenne muscular dystrophy

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Beekman, Chantal ^a   Sipkens, Jessica A ^a   Testerink, Janwillem ^a   Giannakopoulos, Stavros ^a   Kreuger, Dyonne ^a   Van Deutekom, Judith C ^a   Campion, Giles V ^a   De Kimpe, Sjef J ^a   Lourbakos, Afrodite ^a  

^a Prosensa Therapeutics BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN; SPECTRIN;

ARTICLE; AUTOANALYSIS; BECKER MUSCULAR DYSTROPHY; BICEPS BRACHII MUSCLE; CELLULAR DISTRIBUTION; CHEMICAL PARAMETERS; COMPUTER PROGRAM; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; EXON; GASTROCNEMIUS MUSCLE; HISTOGRAM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE PROCESSING; IMMUNOFLUORESCENCE TEST; LIMIT OF DETECTION; MEASUREMENT ACCURACY; MEMBRANE INTENSITY; MUSCLE BIOPSY; MUSCLE CELL; PROCESS OPTIMIZATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUADRICEPS FEMORIS MUSCLE; REPRODUCIBILITY; SARCOLEMMA; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; SOLEUS MUSCLE; STANDARDIZATION; TIBIALIS ANTERIOR MUSCLE; TRICEPS BRACHII MUSCLE; BIOPSY; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; PATHOLOGY; PROCEDURES; SENSITIVITY AND SPECIFICITY; SKELETAL MUSCLE;

BIOPSY; DYSTROPHIN; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MUSCLE FIBERS, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84907275529     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107494     Document Type: Article

References (16)

1. van Deutekom JC, de Kimpe SJ, Campion GC (2013) Antisense oligonucleotides as personalized medicine for Duchenne muscular dystrophy. Drug Discov Today: Ther Strat: doi: 10.1016/j.ddstr.2013.04.001.
2. Nicholson LV, Johnson MA, Gardner-Medwin D, Bhattacharya S, Harris JB (1990) Heterogeneity of dystrophin expression in patients with Duchenne and Becker muscular dystrophy. Acta Neuropathol 80: 239-250.
3. Voit T, Stuettgen P, Cremer M, Goebel HH (1991) Dystrophin as a diagnostic marker in Duchenne and Becker muscular dystrophy. Correlation of immunofluorescence and western blot. Neuropediatrics 22: 152-162.
4. Taylor LE, Kaminoh YJ, Rodesch CK, Flanigan KM (2012) Quantification of dystrophin immunofluorescence in dystrophinopathy muscle specimens. Neuropathol Appl Neurobiol 38: 591-601.
5. Arechavala-Gomeza V, Kinali M, Feng L, Brown SC, Sewry C, et al. (2010) Immunohistological intensity measurements as a tool to assess sarcolemma associated protein expression. Neuropathol Appl Neurobiol 36: 265-274.
6. Arechavala-Gomeza V, Kinali M, Feng L, Guglieri M, Edge G, et al. (2010) Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials. Neuromuscul Disord 20: 295-301.
7. Lourbakos A, Sipkens J, Beekman C, Kreuger D, Brasz L, et al. (2011) The incidence of revertant and trace dystrophin expression in muscle biopsies of Duchenne Muscular Dystrophy patients with different exon deletions [P1.6]. Neuromuscul Disord. 21: 643.
8. van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, et al. (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357: 2677-2686.
9. Nguyen TM, Cartwright AJ, Morris GE, Love DR, Bloomfield JF, et al. (1990) Monoclonal antibodies against defined regions of the muscular dystrophy protein, dystrophin. FEBS Lett 262: 237-240.
10. Nguyen TM, Morris GE (1993) Use of epitope libraries to identify exon-specific monoclonal antibodies for characterization of altered dystrophins in muscular dystrophy. Am J Hum Genet 52: 1
11. Hollinger K, Yang CX, Montz RE, Nonneman D, Ross JW, et al. (2014) Dystrophin insufficiency causes selective muscle histopathology and loss of dystrophin-glycoprotein complex assembly in pig skeletal muscle. FASEB J 28: 1600-1609.
12. Appleyard ST, Dunn MJ, Dubowitz V, Scott ML, Pittman SJ, et al. (1984) Monoclonal antibodies detect a spectrin-like protein in normal and dystrophic human skeletal muscle. Proc Natl Acad Sci U S A 81: 776-780.
13. Repasky EA, Pollina CM, Menold MM, Hudecki MS (1986) Increased concentration of spectrin is observed in avian dystrophic muscle. Proc Natl Acad Sci U S A 83: 802-806.
14. Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, et al. (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose escalation, proof-of-concept study. Lancet Neurol 8: 918-928.
15. Anthony K, Arechavala-Gomeza V, Ricotti V, Torelli S, Feng L, et al. (2014) Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping. JAMA Neurol 71: 32-40.
16. Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, et al. (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378(9791): 595-605.